Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study  by Andersson, Borje S et al.
145B B & M T
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is an established treatment modality for patients
with hematologic malignancies [1]. The most commonly
used pretransplantation conditioning therapy is a combina-
tion of total body irradiation (TBI) and cyclophosphamide
(Cy), possibly with the addition of other cytotoxic agents [2].
Although the delivery of TBI is very precise, it is fraught
with late complications such as cataracts, secondary tumors,
and retardation of physical and intellectual development in
children [3-12]. In addition, TBI is often contraindicated
for patients who have had previous therapeutic radiation
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ABSTRACT
Busulfan (Bu) is commonly used as a component of conditioning regimens for hematopoietic stem cell transplanta-
tion. Precise delivery of the oral formulation is compromised by erratic gastrointestinal absorption. An IV Bu
formulation was developed to provide dose assurance and complete bioavailability. In a phase I study, the plasma
bioequivalence of IV Bu was established at approximately 80% of the oral dose. We now report the findings of the
first phase II study, in which 61 adults with hematologic cancers were treated with a Bu-cyclophosphamide (BuCy)
regimen consisting of IV Bu (0.8 mg/kg every 6 hours × 16) followed by Cy (60 mg/kg qd × 2) and transplantation of
stem cells from an HLA-matched sibling donor. The median age of study participants was 37 years; 75% of patients
had active disease; 48% were heavily pretreated, and 13% had undergone a prior transplantation. Median follow-up
was 2.3 years; median time to engraftment (absolute neutrophil count, >0.5 × 109/L) was 13 days; 100% of patients
with cytogenetic and/or molecular markers had documented chimerism; and there were no engraftment failures.
Two-year overall and disease-free survival were 67% and 42%, respectively. There were no unexpected toxic reac-
tions. Fatal veno-occlusive disease occurred in 2 patients, 1 of whom had undergone a prior transplantation. Treat-
ment-related mortality at 100 days was 9.8% (6/61). Bu pharmacokinetics after IV drug administration demon-
strated high inter- and intrapatient consistency; 86% of patients maintained an area under the curve between 800
and 1500 µMol-min. In conclusion, the IV Bu in this regimen was very well tolerated and demonstrated excellent
antitumor efficacy, most likely because of dose assurance with predictable pharmacokinetics.
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therapy. As an alternative, high-dose oral busulfan (Bu) in
combination with Cy was introduced [13,14]. After modiﬁca-
tion of the Cy dose (BuCy2) [15], this regimen became widely
accepted, and it is now the most commonly used non–TBI-
based pretransplantation conditioning treatment [2].
Although the oral BuCy2 regimen is generally well tol-
erated, there has been concern as to whether oral BuCy2 is
immunosuppressive enough to consistently allow engraft-
ment, especially when the donor is partially mismatched or
when an unrelated donor is used [16-19]. Hepatic and neu-
rological toxicities are also worrisome, particularly in heavily
pretreated patients. Several investigators have associated the
serious side effects of Bu-based therapy with systemic drug
exposure. Thus, a high area under the plasma concentration–
versus–time curve (AUC) has been associated with an
increased risk for hepatic veno-occlusive disease (VOD)
[19-24]. In addition, the hepatic ﬁrst-pass Bu exposure has
been proposed to contribute to VOD [25]. Furthermore,
high Bu levels and consequent drug penetration of the cen-
tral nervous system (CNS) have produced seizures [26,27].
Ljungman et al. suggested that an increased risk for serious
treatment-related toxicity/mortality is connected with high
Bu blood concentrations [28]. Conversely, low Bu AUC lev-
els have been correlated with an increased risk for graft
rejection and leukemic relapse [17-19].
Unpredictable and erratic intestinal absorption of Bu
contributes to wide interpatient variations in bioavailability
and AUC measurements. The interpatient variability associ-
ated with oral Bu has been estimated to be as high as 10-fold
or more [20-23,26,27]. To reduce this variability and
improve the safety of oral Bu administration, a practice of
individualized, targeted dosing evolved [20-22]. Although
this approach is intellectually appealing, it appears to yield an
AUC within the desired interval in only about half of the
patients, making further modiﬁcations of subsequent doses
necessary [19,20,29]. The requirement for dose modiﬁcation
stems from multiple problems inherent with the use of oral
Bu. First, nausea and vomiting due to gastric irritation inter-
feres with intestinal Bu absorption. Second, the interdose
bioavailability may vary as much as 2- to 3-fold [27]. Third,
delayed Bu absorption and elimination occurs in 10% to
25% of the patients, pushing Bu blood concentration to its
maximum more than 6 hours after drug ingestion and thus
greatly interfering with the reliability and reproducibility of
the pharmacokinetic (PK) information [23,30,31]. These
problems have called into question the value to a particular
patient of an individualized dosing strategy [32].
Precise, predictable Bu dosing is important in pretrans-
plantation conditioning therapy, and the unpredictable
bioavailability of oral Bu prompted us to develop an alterna-
tive. We designed a pharmaceutically acceptable intravenous
(IV) Bu formation to address the erratic intestinal absorp-
tion and any hepatic first-pass effect [33,34], then deter-
mined that 0.8 mg/kg IV should yield a median AUC of
1100 to 1200 µMol-min [35]. This IV Bu dose plus Cy in a
modified BuCy2 regimen should be cytoreductive and
immunosuppressive enough to consistently ensure engraft-
ment, yet stay short of the 1500–µMol-min level associated
with an increased risk for serious VOD [23]. A 2-hour infu-
sion was chosen to mimic a typical Bu elimination pattern
following oral dosing.
This IV BuCy2 regimen has now been used without
PK-guided dose adjustment as pretransplantation condition-
ing therapy for patients undergoing allogeneic HSCT for
hematologic cancers. We now report the clinical outcome of
these patients and the PK data obtained.
PATIENTS AND METHODS
Eligibility Criteria
Patients with the following hematologic malignancies
were eligible for this study, provided that they did not qualify
for a protocol of higher institutional priority: (1) acute
leukemia failing induction chemotherapy, in ﬁrst remission
with a high risk for relapse or past ﬁrst remission; (2) chronic
myelogenous leukemia (CML); (3) myelodysplastic syn-
drome (MDS); and (4) primary refractory or resistant
relapsed Hodgkin’s disease (HD) or non-Hodgkin’s lym-
phoma (NHL). Patients were to have a physiologic age
between 15 and 55 years and a Zubrod performance status of
<2. The eligibility criteria also included normal (or with
minor deviations, judged not to be of clinical signiﬁcance)
renal and hepatic function (serum creatinine ≤1.5 mg/100 mL,
bilirubin ≤1.0 mg/100 mL, alanine aminotransferase ≤3× the
upper normal limit), a cardiac left ventricular ejection frac-
tion ≥50%, pulmonary function tests including forced expi-
ratory volume in 1 second (FEV1.0) and diffusion capacity
of the lung for carbon monoxide (DLCO) ≥50% of pre-
dicted, negative serology for hepatitis B and human immuno-
deficiency virus (HIV), and a life expectancy of at least
12 weeks. Patients were also required to have either marrow
or granulocyte colony-stimulating factor (G-CSF)–mobilized
peripheral blood progenitor cells (PBPC) available from an
HLA-matched related donor (without T-cell depletion). All
patients voluntarily signed a written informed consent in
accordance with institutional guidelines.
Preparatory Regimen
The treatment was modiﬁed from Tutschka et al. [15]: Bu
was administered at 0.8 mg/kg body weight IV over 2 hours
every 6 hours for 16 doses followed by Cy at 60 mg/kg IV
over 1 hour for 2 doses on 2 consecutive days. After a day of
rest, the HSCT was performed. The Bu formulation used in
this trial, Busulfex (busulfan) injection, (Orphan Medical,
Minnetonka, MN), consisted of Bu (6 mg/mL) dissolved in
dimethylacetamide (DMA, 33%, vol/vol) and polyethylene
glycol-400 (PEG400, 67%, vol/vol) [33,34]. The IV Bu dose
was diluted in normal saline or 5% dextrose to approxi-
mately 0.5 mg/mL and infused via a controlled-rate infusion
pump through a central venous catheter. The final Bu
administration solution was stable for 8 hours at room tem-
perature and for 12 hours if refrigerated [36]. A ﬁxed-dose
regimen for Bu was used and was calculated based on the
lower of actual or ideal body weight or based on adjusted
ideal body weight, the choice depending on the participat-
ing institution’s practice.
Supportive Care
Phenytoin was administered before and during Bu treat-
ment. MESNA, antiemetics, blood components, and other
supportive measures, such as the use of recombinant G-CSF,
were used according to the guidelines of the participating
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institutions. Prophylaxis against graft-versus-host disease
(GVHD) consisted of tacrolimus or cyclosporin A combined
with low-dose methotrexate (MTX) and/or steroids.
Evaluation of Therapy
Clinical. The clinical end points of the study consisted of
the regimen-related toxicity pattern, engraftment, overall
survival (OS), disease-free survival (DFS), and relapse.
Engraftment was deﬁned as the ﬁrst day the absolute neu-
trophil count (ANC) exceeded 0.5 × 109 cells/L. Failure to
reach an ANC of 0.5×109 cells/L by day 100 after HSCT was
deﬁned as no engraftment. Late graft failure was deﬁned as
initial engraftment with documented donor-derived hemato-
poiesis followed by loss of graft function. Informative cyto-
genetic restriction fragment length polymorphism (RFLP)
and/or ﬂuorescence in situ hybridization (FISH) data were
collected to support the clinical impression of engraftment,
but these assays were not a mandatory part of the protocol,
and the data were not available for all patients. Clinical
remission was defined for patients with leukemia as the
absence of malignant cells in the marrow with normalization
of marrow morphology and peripheral blood counts; for
patients with lymphoma, remission was deﬁned as the resolu-
tion of mass disease on physical examination, computed
tomography (CT) scans, and/or gallium scan, as appropriate.
Time to relapse and progressive disease were calculated from
transplantation to the day of detection. Length of survival
was deﬁned as time from HSCT to the day of death, with the
cause of death noted. Kaplan-Meier estimates were calcu-
lated for OS and DFS [37]. The latter was deﬁned as survival
in continuous clinical remission (CCR): relapse and death
were events, and patients surviving in CCR were censored at
last follow-up. Descriptive statistics were computed for time
to myeloablation, duration of neutropenia, time to engraft-
ment, time to disease progression, and survival.
During hospitalization, all patients were monitored
daily for adverse events and hematologic parameters. Clini-
cal chemistry parameters were evaluated at least twice
weekly. After discharge and up to day 100 post-HSCT, all
patients were followed for treatment-related toxicity
(weekly), for the quality of engraftment, and for relapse.
After HSCT day 100, disease status and survival were fol-
lowed at least quarterly.
Hepatic VOD was diagnosed by each site’s principal
investigator based on clinical examination and laboratory
ﬁndings. This primary assessment was veriﬁed by an inde-
pendent reviewer, who did not participate as a site investiga-
tor. The reviewer retrospectively applied the Jones criteria
[38] to all reported VOD cases. Additionally, he searched
the clinical database for subjects with a bilirubin >2 mg/dL
who also fulfilled at least 1 of the Jones criteria to try to
identify any additional patients with VOD. All other toxic
events were deﬁned by the modiﬁed National Cancer Insti-
tute criteria. Data were collected across all participating
centers on standardized case report forms using prospec-
tively established data collection guidelines. All data were
100% monitored by an independent clinical research associ-
ate. Database entry was double-entry verified and set up
with established edit checks.
Pharmacokinetics. The objective was to describe the PK
characteristics of IV Bu when administered in the prescribed
regimen. Blood samples for assay of Bu concentrations were
drawn in conjunction with the ﬁrst and ninth (steady-state)
infusions: immediately before drug infusion (trough) and at
15, 30, and 45 minutes after the start of infusion, at 5 min-
utes before the end of infusion (peak; end of infusion), and
at 15, 30, 60, 120, 180, and 240 minutes after the end of the
infusion. In addition, a sample was taken immediately before
the 13th infusion (trough) and 5 minutes before its comple-
tion (peak). All blood samples were collected from a periph-
eral IV line. The samples were placed on ice and carried to
the laboratory. After centrifugation in a refrigerated cen-
trifuge, the plasma was cryopreserved at –70°C until assayed
with a gas chromatographic–mass selective detection assay
(GC-MSD) [17, modiﬁed from 39].
The PK parameter calculations were performed with a
noncompartmental subroutine [40]. The peak Bu concentra-
tions (Cmax) and the corresponding peak time (Tmax) were
observed values. The AUC was calculated by the linear
trapezoidal rule; the AUC at dose 1 (AUCinf) included an
extrapolated area to time inﬁnity after the last measurable
plasma concentration, and the AUC at steady state (AUCss)
was calculated for dose 9. The terminal half-life (T1/2) was
obtained by log-linear regression analysis of the terminal
phase of the concentration-versus-time curves. Plasma
clearances (CL for the initial intravenous infusion and CL/F
for the steady-state dose) were determined using the dose-
area relationship and were normalized to actual body
weight. Volume of distribution was determined from the
ratio of the apparent clearance to the elimination rate con-
stant (λΖ). Descriptive statistics were computed for perti-
nent PK parameters for doses 1 and 9, and comparisons of
peak and trough concentrations were done for doses 1, 9,
and 13. Projected dose 9 Cmax was compared with the actual
dose 9 Cmax. The projected dose 9 Cmax was based on dose 1
Cmax multiplied by the accumulation factor (1/1 – e
–λτ),
where λ is the elimination rate constant and τ is the dosing
interval [41]. The Bu plasma analyses were performed at a
centralized laboratory, and all PK analyses were performed
by an independent contractor.
RESULTS
Patient and Disease Characteristics
Sixty-one patients were treated between June 1996 and
December 1997. The demographics of the patients are sum-
marized in Table 1. The median age was 37 years (range,
20-63 years), with 11 patients (18%) aged between 50 to
63 years. There were slightly more men than women enrolled
(36/25). Twenty-six patients (43%) had acute myelogenous
leukemia (AML), 9 (15%) had MDS, 17 (27%) had CML, 5
(8%) had NHL, and 4 (7%) had HD. Most patients (56/61;
92%) were considered to be at high risk for treatment-related
toxicity and recurrent disease, based on any combination of
the following criteria: active disease at the time of transplan-
tation, ≥3 prior chemotherapy regimens, prior radiation ther-
apy, or prior HSCT. Seven of the 11 patients ≥50 years of age
(64%) met the above high-risk criteria.
Most of the patients entered the program at an
advanced stage of disease (Table 1). Four of the AML
patients were refractory to induction chemotherapy, and
8 patients were in first complete remission (CR). Of the
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14 patients beyond ﬁrst CR, 8 patients were in relapse and
6 patients were in remission. Three of the 8 AML patients
in ﬁrst CR and 5 of the 9 MDS patients had a history of a
preceding malignant disease. Eleven of the 17 CML patients
had accelerated-phase disease, and 2 patients were in the
blastic phase. Four of the 5 NHL patients had relapsed
active disease (3 of the 4 patients were refractory to conven-
tional chemotherapy). One patient had both NHL and
MDS but, for the purpose of this analysis, was counted as
having lymphoma. The ﬁfth NHL patient was refractory to
induction chemotherapy. The 4 HD patients had primary
refractory or resistant relapsed disease; 1 of these patients
had progressive disease after a previous autologous HSCT.
Twenty-seven patients (44%) received bone marrow, and
34 patients (56%) had received a PBPC graft.
Toxicity
All patients received the entire IV BuCy2 regimen as
prescribed. In no case was the IV Bu treatment interrupted
because of side effects. Table 2 provides a summary of pri-
mary causes of death for all patients. Up to and including
day 28 after HSCT, 2 patients died (3.3%), 1 of Aspergillus
pneumonia on HSCT day 20, before engraftment could be
evaluated, and the other of cytomegalovirus pneumonia
complicated by diffuse alveolar hemorrhage (DAH) and
acute respiratory distress syndrome (ARDS) on HSCT day
27. Between HSCT days 29 and 100, 6 other patients died, 2
of whom had VOD (HSCT days 30 and 31): 1 was an AML
patient in second CR, and the other was an MDS patient
who underwent a second HSCT (Table 3). One patient died
of pneumonia complicated by DAH (day 62), and 1 patient
died of interstitial pneumonitis (IP)/ARDS (day 98). The lat-
ter patient had previously received 40 Gy mantle radiation
for HD. Two patients died of recurrent leukemia (days 42
and 80). The treatment-related and overall mortality rates in
the ﬁrst 100 days post-HSCT were 9.8% (6/61) and 13.1%
(8/61), respectively.
The CNS, pulmonary, gastrointestinal tract, and hepatic
toxicities are described below.
Central Nervous System. No seizures were reported dur-
ing the deﬁned 36-day study period (HSCT day –7 through
day 28). Three patients experienced hallucinatory events, all
grade 1; 1 event occurred during IV Bu administration and
the other 2 events occurred approximately 3 weeks after the
last IV Bu infusion. Isolated incidents of mild CNS distur-
bances were encountered and resolved. The only exceptions
were seen in the 2 patients with lethal VOD, who became
confused shortly before they died.
Lungs. There were no additional pulmonary adverse
events aside from the above incidents of pneumonia, IP,
and DAH.
Gastrointestinal Tract. There were no grade 4 toxic
events aside from self-limited anorexia in 1 patient (2%).
Four patients (7%) experienced grade 3 nausea; 1 patient
(2%) had grade 3 vomiting. The overall incidence of vomit-
ing during Busulfex administration (days –7 through –4) was
43%; all occurrences were considered mild, of grades 1 or 2.
Twenty-seven patients (44%) developed grade 2 mucositis,
and 16 patients (26%) had grade 3 mucositis lasting a
median of 6 days (range, 2-11 days).
Hepatic. The site investigators recognized 5 incidents of
VOD (5/61; 8.2%). No additional patients were identiﬁed
through a search of the database. VOD resolved in 3 patients
and was fatal in 2 patients (3.3%). The overall incidence of
VOD in patients undergoing their ﬁrst transplantation was
5.7% (3/53), and 1 of them died (1.9%). The independent
reviewer concluded that only 3 of the 5 reported patients
(3/61; 4.9%) fulﬁlled the Jones criteria for VOD [38] (see
Table 1. Patient Demographics and Disease Characteristics*
Demographics n (%)
Age, median (range), y 37 (20-63)
18-29 11 (18)
30-39 21 (34)
40-49 18 (30)
50-64 11 (18)
Sex
Male 36 (59)
Female 25 (41)
Active disease 42 (69)†
Pretreatment 29 (48)
≥3 Chemo regimens 9 (15)
Previous XRT 7 (11)
≥3 Chemo regimens + previous XRT 5 (8)
Previous BMT 8 (13)
Stem cell source
Bone marrow 27 (44)
Peripheral blood 34 (56)
Disease
AML 26 (43)
Induction failure 4 (7)
CR1 8 (13)
>CR1 14 (23)
CML 17 (27)
Chronic phase 4 (7)
Acute phase 11 (18)
Blast crisis 2 (3)
Lymphoma 9 (15)
HD 4 (7)
NHL 5 (8)
MDS 9 (15)
De novo 4 (7)
Secondary 5 (8)
Total 61
*XRT indicates radiation therapy; CR1 indicates patient was in ﬁrst
complete remission; >CR1, patient was beyond CR1.
†Excluding the 4 chronic phase CML patients, who were regarded
as good-risk patients for treatment-related complications.
Table 2. Primary Causes of Death by Study Period
HSCT Study Day Period 
Days –7 Days 29
to 28, n to 100, n
Infection, including pneumonia 1
Pneumonia with secondary DAH 1 1
VOD 2
IP/ARDS 1
GVHD
Disease progression 2
Total 2 6
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Table 3 for details). In addition to the patients who suffered
VOD, increased serum bilirubin (>1.0 mg/dL) was recorded
in 5 patients who had GVHD. Mild, reversible, and self-
limiting increases in serum bilirubin (median, 2.9 mg/dL)
were also recorded in 9 patients during the early posttrans-
plantation period, approximately at the time that low-dose
MTX was given.
Engraftment and Chimerism
All 60 evaluable patients achieved engraftment at a median
of 13 days after transplantation (range, 9-29 days); 1 patient
died prior to engraftment. Patients who received marrow
(n = 27) achieved engraftment in an average of 16 days (range,
11-29 days), whereas those who received PBPC (n = 34)
achieved engraftment in 13 days (range, 9-22 days) (P = .029).
Chemotherapy-induced pancytopenia developed slowly,
with the median time to reach an ANC of <0.5 × 109 cells/L
being HSCT day 4 (range, day –7 to day +5). The median
duration of neutropenia was therefore only a brief 11 days
(range, 6-27 days). The time to engraftment was consider-
ably shorter for the 47 patients who received G-CSF
(12 days; range, 9-22 days) than for the 13 patients who did
not receive G-CSF (18 days; range, 13-29 days). Donor-
derived hematopoiesis was further documented by cytoge-
netic markers and/or FISH and/or RFLP analysis in 43 of
the 60 evaluable patients at 1 and/or 3 months posttrans-
plantation. Eleven patients had indeterminate results
because of the lack of an appropriate marker, and 6 patients
did not have any test performed. All 43 patients (100%) had
documented donor-cell engraftment; 38 patients (88%) had
complete chimerism, and the remaining 5 patients (12%)
had mixed chimerism (RFLP) with host-type DNA con-
tributed by persistent or recurrent leukemic marrow cells.
We did not observe autologous recovery or late graft failure
posttransplantation in any patient who had cytogenetic,
FISH, and/or RFLP data available.
Fifty-three patients (87%) required packed red blood
cell (PRBC) transfusion support, and 60 patients (95%)
received platelet transfusions. The median number of PRBC
and platelet transfusions was 4 (range, 1-12) and 6 (range,
1-27), respectively.
Graft-Versus-Host Disease
Acute GVHD was documented in 13 patients (22%),
with 6 patients (10%) having grades III to IV GVHD. No
patient died of GVHD prior to HSCT day 100, but beyond
HSCT day 100, 3 patients (4.9%) died of GVHD or its sec-
ondary complications.
Response, Relapse, and Survival
The median follow-up time for patients alive, in CCR,
and still available for follow-up (n = 25) was 28 months
(range, 12-39 months). Of the 25 patients, 20 patients had a
DFS of more than 2 years, and 3 patients had a DFS
≥3 years (2 patients were censored in CCR as they were lost
to follow-up at 12 and 17 months). The OS and DFS rates
at 2 years were 67% and 42%, respectively (Figure 1).
Pharmacokinetics
Complete PK proﬁles were assessed at Busulfex doses 1
and 9. Additionally, peak and trough levels were obtained at
dose 13. The analyses were performed on blood samples
obtained from all 61 patients. Ninety-seven percent of
patients (59/61) were evaluable for all PK parameters for
both dose 1 and 9 (61/61 for dose 1 and 59/61 for dose 9).
The resulting parameters are listed in Table 4. Following
the initial dose, the mean AUCinf was 1106 µMol-min
(range, 413-2511 µMol-min), the mean T1/2 was 2.83 hours
(range, 1.69-6.81 hours), and the mean CL normalized to
actual body weight (CL/ABW) was 2.74 mL/min per kg
(range, 1.28-6.00 mL/min per kg). Following dose 9, the
mean AUCss was 1167 µMol-min (range, 556-1673 µMol-
min), the mean T1/2 was 2.99 hours (range, 2.11-5.05 hours),
and the mean CL/ABW was 2.52 mL/min per kg (range,
1.49-4.31 mL/min per kg). The variability around these
3 parameters at steady state was small: the coefficient of
variation (CV) ranged from 19% to 24%.
Without dose adjustment, 55 (90%) of 61 patients had a
dose 1 AUCinf <1500 µMol-min, whereas 55 (93%) of 59
maintained an AUC <1500 µMol-min at dose 9 (steady
state). Eighty-six percent (51/59) of the patients maintained
an AUC between 800 and 1500 µMol-min (the 4 patients
with AUC below 800 µMol-min had AUCs of 556, 741, 771,
and 794 µMol-min; the 4 patients with AUC >1500 µMol-
min had levels of 1586, 1604, 1617, and 1673 µMol-min).
The AUC comparisons between dose 1 and dose 9 are pre-
sented in Figure 2. This graph shows tightly clustered, pre-
dominantly horizontal lines demonstrating both intra- and
interpatient predictability and consistency; the dose 1 out-
lier (AUC = 2511 µMol-min) had an unexplained 6-hour
trough value that yielded a very high residual AUC, but
this value normalized at the dose 9 assessment (Figure 2).
Table 3. Characteristics and Outcome of Patients Developing VOD*
Dose 1 AUC, Dose 9 AUC,
Patient Disease VOD Site† Jones‡ Prior Therapy µMol-min µMol-min Outcome
HD Yes No R,C,T 1256 1170 Resolved
AML Yes Yes C 1106 1194 Died
MDS Yes Yes R 1225 978 Resolved
MDS Yes Yes R,C,T 1644 1617 Died
CML Yes No R 1567 1604 Resolved
*R indicates prior radiation; C, ≥3 prior chemotherapy regimens; T, prior transplantation.
†Diagnosis of VOD by the site principal investigator based on clinical examination and laboratory ﬁndings.
‡Diagnosis of VOD by bilirubin >2 mg/dL with at least 2 of the following 3 ﬁndings: painful hepatomegaly, weight gain ≥5% from baseline,
ascites [38].
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Additionally, a comparison of the mean AUC estimates
between doses 1 and 9, and the peak and trough plasma Bu
concentrations of doses 1, 9, and 13 displayed an excellent
interdose reproducibility (Figure 3). Using a standard for-
mula for calculation of a predicted concentration (see
“Patients and Methods”), the dose 1 Cmax values predicted
the actual dose 9 Cmax values; there was no signiﬁcant differ-
ence between the predicted result (1251.7 ± 399.8 ng/mL)
and the actual result (1221.8 ± 216.1 ng/mL) (P = .615).
A comparison of dose 1 and dose 9 AUC (n = 59)
showed a difference of 5.5% (Figure 3), which was signiﬁ-
cant (P = .042). This difference is expected, because dose 9 is
at steady state. When we applied the 2-sided t test to deter-
mine the 90% conﬁdence interval for the ratio between dose
1 AUCinf and the dose 9 AUCss, we found a 90% conﬁdence
interval of 103.4% to 111.5%. This interval falls within the
deﬁned pharmaceutical deﬁnition of equivalence interval for
bioequivalence (80%-120%). Thus, dose 1 AUCinf predicted
dose 9 AUCss.
DISCUSSION
Our phase II trial of an IV Bu formulation in prepara-
tion for HSCT yielded encouraging results. Two-year OS
and DFS rates were 67% and 42%, respectively. Fatal VOD
occurred in only 2 patients (3.3%), and treatment-related
mortality at 100 days was <10%. The PK data were consis-
tent between dose 1 and steady state (dose 9).
The development of an IV Bu formulation was a logi-
cal step to overcome the bioavailability and dose assurance
Figure 1. The probability of OS and DFS after HSCT using HLA-matched family donors after the IV BuCy2 regimen in patients with advanced
hematologic malignancies.
Figure 2. Individual patient AUC values for dose 1 and dose 9 (59 patients). Interpatient results for the entire group (n = 59) for both dose 1 and
dose 9 are represented vertically and show consistency and predictability across all patients. Results for each patient are represented horizontally
where each line joins a single patient’s dose 1 and dose 9 AUC value (intrapatient results). For details, see text.
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problems associated with oral Bu. It was important to
assure dose equivalency when the change was made from
oral to IV Bu to enable a comparison of the clinical toxicity
profile of the new formulation with that previously experi-
enced with the oral drug. Our phase I study demonstrated
a median bioavailability of 68% of the oral drug [35]. This
result was virtually identical to the 70% bioavailability of
oral high-dose Bu (1 mg/kg) reported by Schuler et al.,
using a dimethyl sulfoxide (DMSO)-based Bu formulation
as the IV reference solution [42]. Similar estimates of oral
drug bioavailability were made by Hassan et al. (68% in
children and 80% in adults) [27]. Furthermore, the median
AUC of oral Bu at 1 mg/kg of approximately 1106 µMol-
min in the phase I study was similar to that reported by
Somlo et al. (1050 µMol-min), who also used an oral dose
of 1 mg/kg [43]. The similarities between the bioavailabil-
ity estimates of different investigators indicated that the
0.8 mg/kg IV dose should be appropriate to use in a modi-
fied BuCy2 regimen for the first large-scale phase II study
of this new formulation.
It is encouraging that the new IV Bu formulation was
very well tolerated, in view of the high proportion of the
patients who had been heavily pretreated. All 61 patients
received all of their scheduled IV Bu doses, and all 60 evalu-
able patients achieved engraftment as assessed with white
blood cell count recovery, and, if samples were available,
confirmed with cytogenetics and/or RFLP studies. Also,
there was no incident of secondary graft failure. All reported
adverse effects were previously described problems, com-
monly encountered following myeloablative conditioning
Figure 3. Graphic illustration of pharmacokinetic results of IV Bu for dose 1 (AUC, Cmin, Cmax), dose 9 (AUC, Cmin, Cmax), and dose 13 (Cmin, Cmax).
 indicates Cmax; , area under the plasma concentration versus time curve; , Cmin.
Table 4. Pharmacokinetics of Busulfex*
AUC, CL/ABW, Vz/ABW,
Dose, mg† Cmax, ng/mL Tmax, h T1/2, h µMol-min‡ mL/min/kg§ L/kg§
Dose 1
Mean 53.53 947 2.16 2.83 1106 2.74 0.64
Median 53.00 937 1.97 2.71 1084 2.63 0.63
SD 9.79 239 0.50 0.76 318 0.82 0.10
CV, % 18.30 25 23 27 29 30 16
Maximum 76.00 1768 4.20 6.81 2511 6.00 1.02
Minimum 33.00 415 0.25 1.69 413 1.28 0.38
Dose 9
Mean 53.53 1222 2.07 2.99 1167 2.52 0.64
Median 53.00 1249 1.95 2.98 1180 2.40 0.61
SD 9.79 216 0.25 0.56 228 0.62 0.20
CV, % 18 18 12 19 20 24 30
Maximum 76.00 1684 3.00 5.05 1673 4.31 1.70
Minimum 33.00 496 1.75 2.11 556 1.49 0.37
*n = 59. Vz/ABW indicates volume of distribution normalized to actual body weight.
†Total busulfan dose (mg) per administration.
‡For dose 1, AUCinf is presented; for dose 9, AUCss for the 6-hour dosing interval is presented.
§All patients were normalized to ABW for analysis.
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therapy, whether based on TBI, on oral Bu, or on alternative
chemotherapy combinations.
The Bu infusion through a central venous catheter
avoided any hepatic ﬁrst-pass effect but brought the possi-
bility that an increased incidence of pulmonary complica-
tions might be encountered. This concern was not validated,
and we did not detect any new side effects that could be
associated with the Bu solvents DMA and PEG400.
The safety of this combination was further evidenced by
the low treatment-related mortality, 3.3% at 28 days and
9.8% at 100 days posttransplantation. The causes of death—
infections, VOD, DAH, IP, and GVHD—have been
described after a variety of conditioning regimens. The inci-
dence of serious but nonlethal toxicity, in particular VOD,
was also very low. The incidence of fatal VOD was 3.3%,
and only 1 of the ﬁrst-transplantation patients died of VOD
(1.9%). These results compare favorably with previously
published reports on the use of high-dose oral Bu-based pre-
transplantation therapy in high-risk patients [44,45], and also
with a group of patients treated (in parallel) with oral BuCy2
at one of the centers participating in the current study [46].
VOD is considered a most serious side effect of high-
dose Bu-based conditioning therapy. Although several fac-
tors can predispose a patient to develop VOD, it appears to
be more prevalent in patients whose Bu AUC is excessive
(≥1500 µMol-min) [21-23], but not all investigators agree
[32]. We did not ﬁnd a predictive correlation between high
AUC values and VOD in our patients [47]. Such an associa-
tion may exist but be obscured by the low incidence of VOD
in the present study, and the tight range of AUC values
with the new drug formulation may make the association
difﬁcult to conﬁrm.
The ﬁxed Bu dose of 0.8 mg/kg in this combination was
confirmed as clinically appropriate; all evaluable patients
achieved engraftment, and the DFS at 2 years was 42%
(median follow-up, 2.3 years). Furthermore, this dose was
well tolerated, and we did not ﬁnd any increase in serious
complications in older patients [48]. Based on our results,
we suggest that an age above 50 years should not disqualify a
patient with otherwise good performance status from allo-
geneic HSCT using a myeloablative IV Bu–based condi-
tioning regimen.
In a review of oral Bu, Vassal [30] concluded that sys-
temic exposure may vary by a factor as high as 20 from one
patient to another with a ﬁxed-dose oral Bu regimen, greatly
influencing toxic and therapeutic effects. PK-guided dose
adjustment has been advocated to reduce interpatient vari-
ability in systemic Bu exposure, thereby controlling toxicity
and retaining or increasing therapeutic efficacy [20-22].
Slattery et al. deﬁned a lower limit of acceptable Bu concen-
tration at steady state (Css) to decrease the risk for graft
rejection and/or leukemic relapse. This concentration was
dependent on the degree of compatibility of the allogeneic
graft. They suggested that a Css of at least 200 ng/mL (in
the current study, corresponding to an AUC of approxi-
mately 300 µMol-min) is necessary to avoid rejection of a
matched sibling graft, and that a Css of 600 ng/mL (AUC of
approximately 900 µMol-min) is needed to insure engraft-
ment when HLA–partially mismatched related or HLA-
matched unrelated donors were used [17]. This group also
reported a correlation between a high Css (>917 ng/mL;
AUC of approximately 1350 µMol-min) and a low risk of
leukemia recurrence after HSCT for CML [18].
Furthermore, Deeg et al. [49] reported that the use of
oral BuCy2 with PK-guided dose adjustment to achieve Css
plasma levels of 600 to 900 ng/mL (AUC of approximately
900-1350 µMol-min) yielded longer DFS than did oral
BuCy2 without PK monitoring or with the use of Cy-TBI as
conditioning therapy in older MDS patients (>55 years)
undergoing allogeneic HSCT. In our study with the ﬁxed-
dose regimen, the median AUCss was 1167 µMol-min (range,
566-1673 µMol-min), and 81% of the patients had an AUCss
in the range of 900 to 1350 µMol-min ± 5%. This result
actually represents a tighter AUC interval than would be
expected if oral Bu were used in conjunction with PK-guided
individualized dosing [19,23,29]. IV Bu had consistent inter-
and intrapatient PK, as demonstrated by the similarity both in
the median AUCs of the ﬁrst and ninth (steady state) doses
and in peak and trough levels obtained at the ﬁrst, ninth, and
13th doses. There was no statistically signiﬁcant difference
between the actual dose 9 Cmax and the predicted dose 9 Cmax
value based on dose 1 PK. The AUC showed similar high
reproducibility from dose 1 to dose 9. These data support the
utility of a fixed-dose regimen to achieve acceptable PK
parameters in the vast majority of patients. However, it must
be recognized that no patient in our study received a partially
matched or matched unrelated-donor graft.
The PK analysis showed similar values for AUC, clear-
ance, and T1/2 of the new IV Bu compared to published data
for Bu obtained with the oral drug [21-23,27-32], and there
were no signiﬁcant changes in clearance, T1/2, or AUC after
doses 1 and 9. The ﬁndings suggest that the solvent vehicle
does not signiﬁcantly inﬂuence human Bu metabolism. The
high interdose reproducibility of all PK parameters was docu-
mented by the available mean values of AUC, clearance, T1/2,
Cmax, and Cmin after doses 1 and 9, and Cmax and Cmin at doses
1, 9, and 13. This reproducibility is in contrast to the ﬁndings
of high interdose variability between consecutive trough val-
ues reported with the use of oral Bu [31], probably because of
elimination of the erratic intestinal oral drug absorption.
Improved investigator-controlled Bu dosing and pre-
dictable drug exposure with this pharmaceutically acceptable
IV formulation offers an opportunity to explore other dosing
regimens and compare outcomes with the confidence that
drug delivery is well standardized. Investigations using PK-
directed dosing regimens become especially appealing if
sampling strategies using a limited number of samples can be
applied. Hassan et al. showed a high correlation (r = 0.998,
P < .0001, n = 40) between the estimated and the determined
AUC from a sampling strategy based on 3 concentrations
compared with that using a “complete set” of 10 to 13 blood
samples [50]. Similarly, Perry et al. reported a high degree of
reproducibility with a strategy based on 5 samples in patients
treated with the new IV Bu formulation [51].
In summary, the good clinical tolerance paired with a
modest incidence of serious toxicity, a highly reproducible
PK proﬁle (both intra- and interpatient), and a DFS rate of
42% at 2 years posttransplantation in patients with mostly
advanced, heavily pretreated hematological cancers demon-
strate that the new IV Bu formulation may have advantages
over the standard Bu tablets in high-dose chemotherapy.
The parenteral administration of Bu allows for predictable
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systemic exposure without PK monitoring. However, if one
elects to use PK monitoring and targeted dosing, this for-
mulation is a tool to insure standardized drug delivery with
the ability to use dose 1 or test dose PK data to predict
steady-state levels and perform individualized dose adjust-
ments with high precision.
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